Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Authors
Qiu, B.Cai, K.
Chen, C.
Chen, J.
Chen, K. N.
Chen, Q. X.
Cheng, C.
Dai, T. Y.
Fan, J.
Fan, Z.
Hu, J.
Hu, W. D.
Huang, Y. C.
Jiang, G. N.
Jiang, J.
Jiang, T.
Jiao, W. J.
Li, H. C.
Li, Q.
Liao, Y. D.
Liu, H. X.
Liu, J. F.
Liu, L.
Liu, Y.
Long, H.
Luo, Q. Q.
Ma, H. T.
Mao, N. Q.
Pan, X. J.
Tan, F.
Tan, L. J.
Tian, H.
Wang, D.
Wang, W. X.
Wei, L.
Wu, N.
Wu, Q. C.
Xiang, J.
Xu, S. D.
Yang, L.
Zhang, H.
Zhang, L.
Zhang, P.
Zhang, Y.
Zhang, Z.
Zhu, K.
Zhu, Y.
Um, S. W.
Oh, I. J.
Tomita, Y.
Watanabe, S.
Nakada, T.
Seki, N.
Hida, T.
Sasada, S.
Uchino, J.
Sugimura, H.
Dermime, S.
Cappuzzo, F.
Rizzo, S.
Cho, W. C.
Crucitti, P.
Longo, F.
Lee, K. Y.
De Ruysscher, D.
Vanneste, B. G. L.
Furqan, M.
Sieren, J. C.
Yendamuri, S.
Merrell, K. W.
Molina, J. R.
Metro, G.
Califano, Raffaele
Bongiolatti, S.
Provencio, M.
Hofman, P.
Gao, S.
He, J.
Affiliation
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaIssue Date
2021
Metadata
Show full item recordCitation
Qiu B, Cai K, Chen C, Chen J, Chen K-N, Chen Q-X, et al. Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer [Internet]. Vol. 10, Translational Lung Cancer Research. AME Publishing Company; 2021. p. 3713–36.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr-21-634PubMed ID
34733623Additional Links
https://dx.doi.org/10.21037/tlcr-21-634Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr-21-634
Scopus Count
Collections
Related articles
- Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.
- Authors: Lim JU, Kang HS
- Issue date: 2021 Sep
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
- Authors: Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS
- Issue date: 2018 Jul 17
- Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.
- Authors: Facchinetti F, Tiseo M, Bertolaccini L
- Issue date: 2021 Dec
- [Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].
- Authors: Expert Committee on Vessel Targeted Therapy of Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology, Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology
- Issue date: 2020 Dec 23
- [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
- Authors: Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Pathology of Chinese Society of Clinical Oncology, Expert Committee on Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology
- Issue date: 2020 Jul 23
Related items
Showing items related by title, author, creator and subject.
-
Pan-cancer analysis of whole genomesCampbell, P. J.; Getz, G.; Korbel, J. O.; Stuart, J. M.; Jennings, J. L.; Stein, L. D.; Perry, M. D.; Nahal-Bose, H. K.; Ouellette, B. F. F.; Li, C. H.; et al. (2020)Fibrosis and fat replacement in skeletal muscle are major complications that lead to a loss of mobility in chronic muscle disorders, such as muscular dystrophy. However, the in vivo properties of adipogenic stem and precursor cells remain unclear, mainly due to the high cell heterogeneity in skeletal muscles. Here, we use single-cell RNA sequencing to decomplexify interstitial cell populations in healthy and dystrophic skeletal muscles. We identify an interstitial CD142-positive cell population in mice and humans that is responsible for the inhibition of adipogenesis through GDF10 secretion. Furthermore, we show that the interstitial cell composition is completely altered in muscular dystrophy, with a near absence of CD142-positive cells. The identification of these adipo-regulatory cells in the skeletal muscle aids our understanding of the aberrant fat deposition in muscular dystrophy, paving the way for treatments that could counteract degeneration in patients with muscular dystrophy.
-
Generating synthetic computed tomography for radiotherapy: SynthRAD2023 challenge reportHuijben, E. M. C.; Terpstra, M. L.; Galapon, A. J.; Pai, S.; Thummerer, A.; Koopmans, P.; Afonso, M.; van Eijnatten, M.; Gurney-Champion, O.; Chen, Z.; et al. (2024)Radiation therapy plays a crucial role in cancer treatment, necessitating precise delivery of radiation to tumors while sparing healthy tissues over multiple days. Computed tomography (CT) is integral for treatment planning, offering electron density data crucial for accurate dose calculations. However, accurately representing patient anatomy is challenging, especially in adaptive radiotherapy, where CT is not acquired daily. Magnetic resonance imaging (MRI) provides superior soft-tissue contrast. Still, it lacks electron density information, while cone beam CT (CBCT) lacks direct electron density calibration and is mainly used for patient positioning. Adopting MRI-only or CBCT-based adaptive radiotherapy eliminates the need for CT planning but presents challenges. Synthetic CT (sCT) generation techniques aim to address these challenges by using image synthesis to bridge the gap between MRI, CBCT, and CT. The SynthRAD2023 challenge was organized to compare synthetic CT generation methods using multi-center ground truth data from 1080 patients, divided into two tasks: (1) MRI-to-CT and (2) CBCT-to-CT. The evaluation included image similarity and dose-based metrics from proton and photon plans. The challenge attracted significant participation, with 617 registrations and 22/17 valid submissions for tasks 1/2. Top-performing teams achieved high structural similarity indices (≥0.87/0.90) and gamma pass rates for photon (≥98.1%/99.0%) and proton (≥97.3%/97.0%) plans. However, no significant correlation was found between image similarity metrics and dose accuracy, emphasizing the need for dose evaluation when assessing the clinical applicability of sCT. SynthRAD2023 facilitated the investigation and benchmarking of sCT generation techniques, providing insights for developing MRI-only and CBCT-based adaptive radiotherapy. It showcased the growing capacity of deep learning to produce high-quality sCT, reducing reliance on conventional CT for treatment planning.
-
Quality of life issues in patients with bone metastases: a systematic reviewRajeswaran, T.; Wong, H. C. Y.; Zhang, E.; Kennedy, S. K. F.; Gojsevic, M.; Soliman, H.; Vassiliou, V.; Rades, D.; Bonomo, P.; Lee, S. F.; et al. (2023)INTRODUCTION: Bones are frequent sites of metastatic disease, observed in 30-75% of advanced cancer patients. Quality of life (QoL) is an important endpoint in studies evaluating the treatments of bone metastases (BM), and many patient-reported outcome tools are available. The primary objective of this systematic review was to compile a list of QoL issues relevant to BM and its interventions. The secondary objective was to identify common tools used to assess QoL in patients with BM, and the QoL issues they fail to address. METHODS: A search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases between 1946 and 27 January 2023 with the keywords 'bone metastases', 'quality of life', and 'patient reported outcomes'. Specific QoL issues in original research studies and the QoL tools used were extracted. RESULTS: The review identified the QoL issues most prevalent to BM in the literature. Physical and functional issues observed in patients included pain, interference with ambulation and daily activities, and fatigue. Psychological symptoms, such as helplessness, depression, and anxiety were also common. These issues interfered with patients' relationships and social activities. Items not mentioned in existing QoL tools were related to newer treatments of BM, such as pain flare, flu-like symptoms, and jaw pain due to osteonecrosis. CONCLUSIONS: This systematic review highlights that QoL issues for patients with BM have expanded over time due to advances in BM-directed treatments. If they are relevant, additional treatment-related QoL issues identified need to be validated prospectively by patients and added to current assessment tools.